GLB1

Across TCGA pan-cancer cohorts, GLB1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GLB1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GLB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLB1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

LIHC, UCEC, and BLCA are the cancer types where GLB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.148	0.781	<.001	42	view →
UCEC	DFS	Median	All	1.000	0.619	.008	14	view →
BLCA	OS	Median	II,III,IV	1.000	0.414	.040	4	view →
LUSC	DFS	Median	All	0.165	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GLB1–LIHC (OS)

Open the LIHC breakdown →